New combo therapy aims to shrink hard-to-treat tumors in young patients
NCT ID NCT04890093
First seen Jan 17, 2026 · Last updated Apr 29, 2026 · Updated 13 times
Summary
This study tests whether adding the experimental drug PEN-866 to two standard chemotherapy drugs (vincristine and temozolomide) can help adolescents and young adults (ages 12–39) whose solid tumors have come back or stopped responding to treatment. The goal is to find the safest dose and see if the combination shrinks tumors. Participants receive up to 18 cycles of treatment and are followed for long-term effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHABDOMYOSARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Childrens National Medical Center
Washington D.C., District of Columbia, 20010, United States
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.